Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results

- Dermata expects to announce topline results from its XYNGARI™ Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial by end of March 2025 -- The Company recently entered into a Clinical Trial Collaboration Agreement with …
Jetzt den vollständigen Artikel lesen